NovoCure (Nasdaq: NVCR), a developer of most cancers therapies by focusing electrical fields on the expansion, reported $184 million income for the second quarter of 2026, 16% greater than within the corresponding quarter of 2025, and above the consensus analysts’ estimate of $172 million.
The corporate’s share worth has jumped by practically 25% in as we speak’s session to this point, giving it a market cap of two.25 billion. The corporate raised its 2026 income steering from $690-710 million to $710-725 million.
Within the present quarter, the corporate posted income of $5.4 million from its comparatively new product for treating lung most cancers, Optune Lua. That is virtually double the income from the product within the first quarter (it was not in the marketplace within the corresponding quarter).
Specialists have been divided on how the market would settle for this product, and puzzled how far the outcomes of the medical trials would persuade docs to undertake it. The even newer product for treating pancreatic most cancers, which was accredited on the market solely in February, generated income of $1.6 million within the second quarter. NovoCure expects income of $20-30 million in 2026 as an entire from these two merchandise.
The profitable launch of the brand new merchandise is essential for the corporate in its principal market, the therapy of mind most cancers, during which it appeared to have reached saturation lately, notably within the US market. The expansion in income from this product got here primarily exterior the US, whereas US gross sales have been flat.
On the way in which to profitability
Within the coming 12 months, NovoCure is anticipated to turn into nearer to 2 extra new markets. Within the fourth quarter of 2026, the US Meals and Drug Administration is because of determine whether or not to offer approval to the corporate’s product for treating metastases within the mind from lung most cancers. In the identical quarter, NovoCure is anticipated to finish recruitment of sufferers for a Section III trial of its product for first-line therapy of glioblastoma, a type of mind most cancers. A profitable trial will allow NovoCure to supply its product at an earlier stage of the illness, and therefore to extra sufferers for an extended time frame.
NovoCure’s second quarter web loss was smaller than anticipated, at $15 million, or $0.13 per share. Analysts had estimated a lack of $0.33 per share. The narrower loss was partly because of an enchancment within the firm’s gross revenue margin, from 74% to 78%.
NovoCure, which had $440 million money on the finish of the second quarter, has not been worthwhile since 2019, due to heavy funding in medical trials and advertising. CEO Frank Leonard, who took up his put up on the finish of 2025, burdened at first of this 12 months that he was lastly steering the corporate in direction of profitability.
Printed by Globes, Israel enterprise information – en.globes.co.il – on July 23, 2026.
© Copyright of Globes Writer Itonut (1983) Ltd., 2026.
